Laparoscopic removal of splenic artery aneurysm with spleen preservation
Clinical Study on Laparoscopic Resection of Splenic Artery Aneurysm With Preservation of Spleen
This study tries a minimally invasive laparoscopic operation that removes splenic artery aneurysms while saving the spleen in patients with aneurysms that are large, ruptured, or growing quickly, and checks immune function and nearby blood flow over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Northern Jiangsu People's Hospital Academic / other |
| Locations | 1 site (Yangzhou, Jiangsu) |
| Trial ID | NCT07053605 on ClinicalTrials.gov |
What this trial studies
Patients meeting inclusion criteria undergo preoperative evaluation and standardized laparoscopic resection of the splenic artery aneurysm performed by a single surgical team, with the spleen preserved. The same nursing team provides standardized postoperative care and a defined treatment protocol including medications and any additional therapies. Blood tests, liver and coagulation panels, immune function markers, and Doppler hemodynamics of the splenic vein, proper hepatic artery, and portal vein are measured before surgery and at 7 days, 1 month, 3 months, 6 months, and 12 months after surgery. Outcomes focus on changes in immune parameters and regional hemodynamics and their relationship to clinical recovery.
Who should consider this trial
Good fit: Adults with a splenic artery aneurysm located on the main trunk that is >2 cm, ruptured, or growing >0.5 cm per year who can consent and undergo laparoscopic surgery are the intended participants.
Not a fit: People with active malignancy, cirrhosis with portal hypertension, recent peptic ulcer disease, recent hemorrhagic stroke, pregnancy, serious hematologic disorders, uncontrolled hypertension, or HIV are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the procedure could lower rupture risk while preserving spleen function and minimizing adverse changes in immune markers and portal/hepatic/splenic blood flow.
How similar studies have performed: Case series and reports of both laparoscopic and endovascular treatment of splenic artery aneurysms have shown favorable short-term outcomes, but there is limited high-quality comparative evidence on long-term immune and hemodynamic effects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Asymptomatic splenic artery aneurysms with a diameter\>2 cm,ruptured splenic artery aneurysms,and splenic artery aneurysms with a diameter increase\>0.5 cm/year. Aneurysm located in the main trunk of the splenic artery. Informed consent to participate in the study. Exclusion Criteria: * Patients with malignancies Hepatic cirrhosis with portal hypertension peptic ulcer disease Recent peptic ulcer disease History of Hemorrhagic stroke Pregnancy hematological diseases Uncontrolled Hypertension Human immunodeficiency virus (HIV) infection
Where this trial is running
Yangzhou, Jiangsu
- Clinical Medical College, Yangzhou University — Yangzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Guo-Qing Jiang
- Email: jgqing2003@hotmail.com
- Phone: +8651487373382
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.